New-onset diabetes after hemodialysis initiation: Impact on survival

American Journal of Nephrology

Volumn 31, Issue 3, 2010, Pages 239-246

  Salifu, Moro O ^a   Abbott, Kevin C ^c,d   Aytug, Serhat ^b   Hayat, Amir ^a   Haria, Dhiren M ^a   Shah, Syed ^a   Friedman, Eli A ^a   Delano, Barbara G ^a   McFarlane, Samy I ^a   Hurst, Frank P ^c,d   Flom, Peter L ^a   Jindal, Rahul M ^c,e,f  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Crystal Run Healthcare   (United States)

^c Organ Transplant Program   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

^f GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Diabetes; End stage renal disease; Hemodialysis; Mortality; New onset diabetes after initiation of hemodialysis (NODAD); NODAD; NODAD, survival

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; FEMALE; FOLLOW UP; HAZARD RATIO; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PRIORITY JOURNAL; RISK; SURVIVAL;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK FACTORS;

EID: 73649115252     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276542     Document Type: Article

References (36)

1. US Renal Data System: USRDS 2004 Annual Data Report. The National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md.
2. Centers for Disease Control and Prevention (CDC): Incidence of end-stage renal disease among persons with diabetes - United States, 1990-2002. MMWR Morb Mortal Wkly Rep 2005; 54: 1097-1100.
3. Longnecker JC, Klag MJ, Coresh J, et al: Validation of co-morbid conditions on ESRD Medical Evidence Report: the CHOICE study. J Am Soc Nephrol 2000; 11: 520-529.
4. Longnecker JC, Coresh J, Powe NR, et al: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population. The CHOICE study. J Am Soc Nephrol 2002; 13: 1918-1927.
5. Khan MA, Collins AJ, Keane WF: Diabetes in the elderly population. Adv Ren Replace Ther 2000; 7: 32-51.
6. Harding AH, Griffin SJ, Wareham NJ: Population impact of strategies for identifying groups at high risk of type 2 diabetes. Prev Med 2006; 42: 364-368.
7. Egede LE, Zheng D: Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med 2002; 162: 427-433.
8. American Diabetes Association: Clinical practice recommendations 1997. Diabetes Care 1997; 20(suppl 1):S1-S70.
9. Tokars J, Frank M, Alter M, Arduino MJ: National surveillance of dialysis associated diseases in the United States. Semin Dial 2002; 15: 162-171.
10. Shintani Y, Fujie H, Miyoshi H, et al: Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848.
11. Stenvinkel P, Heirnburger O, Paultre F, et al: Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899-1911.
12. Pecoits-Filho R, Lindholrn B, Stenvinkel P: The malnutrition, inflammation and atherosclerosis (MIA) syndrome - the heart of the matter. Nephrol Dial Transplant 2002; 17(suppl 11):28-31.
13. Thorand B, Lowel H, Schneider A, Kolb H, Meisinger C, Frohlich M, Koenig W: C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men; results from the MONICA Ausburg Cohort Study, 1984-1998. Arch Intern Med 2003; 163: 93-99.
14. Helmerson J, Vessby B, Larsson A, Basu S: Association of type 2 diabetes with cyclooxygenase medicated inflammation and oxidative stress in an elderly population. Circulation 2004; 109: 1729-1734.
15. McFarlane SI, Banerji M, Sowers JR: Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-718.
16. Woodward RS, Schnitzler MA, Baty J, et al: Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590-598.
17. Centers for Disease Control and Prevention (CDC): National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Data computed by personnel in CDC's Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion (accessed Sept 10, 2008 at http://www.cdc.gov/diabetes/ statistics/incidence/ fig2.htm).
18. Centers for Disease Control and Prevention (CDC): National Center for Health Statistics, Division of Health Interview Statistics, data from the National Health Interview Survey. Data computed by personnel in CDC's Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion (accessed Sept 10, 2008 at http://www.cdc.gov/diabetes/ statistics/prev/ national/figage.htm).
19. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM: Identifying persons with diabetes using Medicare claims data. Am J Med Qual 1999; 14: 270-277.
20. Shariff SZ, Cuerden MS, Jain AK, Garg AX: The secret of immortal time bias in epidemiologic studies. J Am Soc Nephrol 2008; 19: 841-843.
21. Suissa S: Immortal time bias in pharmacoepidemiology. Am J Epidemiol 2008; 167: 492-499.
22. Gregg EW, Cadwell BL, Cheng YJ, et al: Trends in the prevalence and ratio of diagnosed to undiagnosed diabetes according to obesity levels in the US. Diabetes Care 2004; 27: 2806-2812.
23. Haffner SM: Epidemiology of type 2 diabetes: risk factors. Diabetes Care 1998; 21(suppl 3):C3-C6.
24. Egede LE, Zheng D: Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med 2002; 162: 427-433.
25. Ohsawa M, Kato K, Itai K, et al: Cardiovascular risk factors in hemodialysis patients: results from baseline data of kaleidoscopic approaches to patients with end-stage renal disease study. J Epidemiol 2005; 15: 96-105.
26. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337
27. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280.
28. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001; 38: 1408-1413.
29. Federici M, Lauro R: Diabetes and atherosclerosis - running on a common road. Aliment Pharmacol Ther 2005; 22(suppl 2):11-15.
30. Rodriguez-Manas L, Angulo J, Vallejo S, et al: Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocininduced diabetic rats vasculature. Diabetologia 2003; 46: 556-566.
31. Renard C, Van Obberghen E: Role of diabetes in atherosclerotic pathogenesis. What have we learned from animal models? Diabetes Metab 2006; 32: 15-29.
32. How good are the data? USRDS data validation special study. Am J Kidney Dis 1992; 20(suppl 2):68-83.
33. Mitka M: Hemoglobin A1c poised to become preferred test for diagnosing diabetes. JAMA 2009; 301: 1528.
34. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30(suppl 1):S42-S47.
35. Edelman D, Olsen MK, Dudley TK, Harris AC, Oddone EZ: Utility of hemoglobin A1c in predicting diabetes risk. J Gen Intern Med 2004; 19: 1175-1180.
36. Rohlfing CL, Little RR, Wiedmeyer HM, et al: Use of GHb (HbA1c) in screening for undiagnosed diabetes in the US population. Diabetes Care 2000; 23: 187-191.